J&J Delivers Promising Rybrevant and Lazertinib Combo Results in NSCLC Trial

When treating non-small cell lung cancer (NSCLC), Johnson & Johnson’s chemotherapy-free Rybrevant and Lazcluze combo has shown encouraging long-term outcomes. These results, presented at the World Conference on Lung Cancer, highlight the regimen’s potential as a first-instance treatment and follow its recent FDA approval for patients with certain mutations.

The phase 3 trial assessed the effectiveness of the Rybrevant and Lazcluze combination compared to AstraZeneca’s Tagrisso for NSCLC patients with mutations. With a median follow-up of 31.1 months, 61% of patients receiving the J&J combination were still alive, compared to 53% of those on Tagrisso. The combination also demonstrated superior control of central nervous system disease and longer treatment durability.

This development is significant given that NSCLC represents up to 85% of lung cancer cases. Importantly, around 39% of EGFR-mutated NSCLC patients do not receive second-instance therapy due to disease progression and resistance following initial monotherapy.

In the shifting NSCLC treatment landscape, J&J’s Rybrevant and Lazcluze combination stands out as a promising chemotherapy alternative. Joshua Bauml from J&J expressed enthusiasm about the findings and the anticipation for additional data, suggesting that this advancement could significantly influence future treatment strategies and patient outcomes.